Literature DB >> 12101391

Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update.

C Soldani1, A Ivana Scovassi.   

Abstract

Poly(ADP-ribosylation) is a post-translational modification of proteins playing a crucial role in many processes, including DNA repair and cell death. The best known poly(ADP-ribosylating) enzyme, PARP-1, is a DNA nick sensor and uses betaNAD(+) to form polymers of ADP-ribose which are further bound to nuclear protein acceptors. To strictly regulate poly(ADP-ribose) turnover, its degradation is assured by the enzyme poly(ADP-ribose) glycohydrolase (PARG). During apoptosis, PARP-1 plays two opposite roles: its stimulation leads to poly(ADP-ribose) synthesis, whereas caspases cause PARP-1 cleavage and inactivation. PARP-1 proteolysis produces an 89 kDa C-terminal fragment, with a reduced catalytic activity, and a 24 kDa N-terminal peptide, which retains the DNA binding domains. The fate and the possible role of these fragments during apoptosis will be discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12101391     DOI: 10.1023/a:1016119328968

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  222 in total

1.  Induction of apoptosis by 3-amino-6-(3-aminopropyl)-5,6-dihydro-5,11-dioxo-11H-indeno[1,2-c]isoquinoline via modulation of MAPKs (p38 and c-Jun N-terminal kinase) and c-Myc in HL-60 human leukemia cells.

Authors:  Eun-Jung Park; Evgeny Kiselev; Martin Conda-Sheridan; Mark Cushman; John M Pezzuto
Journal:  J Nat Prod       Date:  2011-12-07       Impact factor: 4.050

2.  Silencing of skeletal metastasis-associated genes impairs migration of breast cancer cells and reduces osteolytic bone lesions.

Authors:  Christina Reufsteck; Rinat Lifshitz-Shovali; Michael Zepp; Tobias Bäuerle; Dieter Kübler; Gershon Golomb; Martin R Berger
Journal:  Clin Exp Metastasis       Date:  2012-03-11       Impact factor: 5.150

3.  Adenosine A2A receptor inactivation increases survival in polymicrobial sepsis.

Authors:  Zoltán H Németh; Balázs Csóka; Jeanette Wilmanski; Dazhong Xu; Qi Lu; Catherine Ledent; Edwin A Deitch; Pál Pacher; Zoltán Spolarics; György Haskó
Journal:  J Immunol       Date:  2006-05-01       Impact factor: 5.422

4.  Synthesis and antitumor activity of 1,5-disubstituted 1,2,4-triazoles as cis-restricted combretastatin analogues.

Authors:  Romeo Romagnoli; Pier Giovanni Baraldi; Olga Cruz-Lopez; Carlota Lopez Cara; Maria Dora Carrion; Andrea Brancale; Ernest Hamel; Longchuan Chen; Roberta Bortolozzi; Giuseppe Basso; Giampietro Viola
Journal:  J Med Chem       Date:  2010-05-27       Impact factor: 7.446

5.  A novel aminosaccharide compound blocks immune responses by Toll-like receptors and nucleotide-binding domain, leucine-rich repeat proteins.

Authors:  Kyoung-Hee Lee; Yuen-Joyce Liu; Amlan Biswas; Chikako Ogawa; Koichi S Kobayashi
Journal:  J Biol Chem       Date:  2010-12-07       Impact factor: 5.157

6.  Sublytic complement protects prostate cancer cells from tumour necrosis factor-α-induced cell death.

Authors:  L Liu; W Li; Z Li; M Kirschfink
Journal:  Clin Exp Immunol       Date:  2012-08       Impact factor: 4.330

7.  p21 overexpression sensitizes osteosarcoma U2OS cells to cisplatin via evoking caspase-3 and Bax/Bcl-2 cascade.

Authors:  Yong Ding; Yucai Wang; Jun Chen; Yunsheng Hu; Zhuo Cao; Pengcheng Ren; Yong Zhang
Journal:  Tumour Biol       Date:  2013-12-11

8.  MRPL33 and its splicing regulator hnRNPK are required for mitochondria function and implicated in tumor progression.

Authors:  L Liu; C Luo; Y Luo; L Chen; Y Liu; Y Wang; J Han; Y Zhang; N Wei; Z Xie; W Wu; G Wu; Y Feng
Journal:  Oncogene       Date:  2017-09-04       Impact factor: 9.867

9.  Reevesioside F induces potent and efficient anti-proliferative and apoptotic activities through Na⁺/K⁺-ATPase α3 subunit-involved mitochondrial stress and amplification of caspase cascades.

Authors:  She-Hung Chan; Wohn-Jenn Leu; Lih-Ching Hsu; Hsun-Shuo Chang; Tsong-Long Hwang; Ih-Sheng Chen; Ching-Shih Chen; Jih-Hwa Guh
Journal:  Biochem Pharmacol       Date:  2013-10-04       Impact factor: 5.858

10.  Targeted Therapy for EBV-Associated B-cell Neoplasms.

Authors:  Siddhartha Ganguly; Sudhakiranmayi Kuravi; Satyanarayana Alleboina; Giridhar Mudduluru; Roy A Jensen; Joseph P McGuirk; Ramesh Balusu
Journal:  Mol Cancer Res       Date:  2018-11-28       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.